GlassScriptPhysician profile
Saad A Shakir
NPI 1245367374
$66,377.05
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $13K · 2021: $7,077 · 2022: $20K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $28,225.82 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $24,184.02 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,696.14 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $1,382.30 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $1,243.99 | 2019-2022 | |
| Lundbeck LLC | $1,207.12 | 2019-2022 | |
| Brainsway USA INC | $1,074.91 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $1,028.45 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $975.06 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $881.16 | 2020-2022 | |
| Neuronetics, INC. | $770.15 | 2022 | |
| Vanda Pharmaceuticals INC. | $698.22 | 2019-2022 | |
| Alkermes, INC. | $426.76 | 2021-2022 | |
| Bausch Health US, LLC | $394.18 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $357.17 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $262.69 | 2021-2022 | |
| Shire North American Group INC | $243.02 | 2019 | |
| Abbvie INC. | $176.90 | 2021-2022 | |
| Alfasigma USA, INC. | $161.61 | 2020-2022 | |
| Eisai INC. | $133.02 | 2020-2021 | |
| Corium, LLC | $116.70 | 2022 | |
| Adlon Therapeutics L.P. | $110.93 | 2021 | |
| Allergan, INC. | $89.94 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $89.79 | 2021-2022 | |
| Amgen INC. | $76.22 | 2019 | |
| Indivior INC. | $70.54 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $65.41 | 2019 | |
| Noven Pharmaceuticals, INC. | $36.18 | 2020 | |
| Novartis Pharmaceuticals Corporation | $33.46 | 2019-2020 | |
| Livanova USA, INC. | $26.81 | 2020 | |
| Supernus Pharmaceuticals, INC. | $24.07 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $21.47 | 2021 | |
| Noven Therapeutics, LLC | $20.82 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $20.45 | 2019 | |
| Almatica Pharma LLC | $18.07 | 2022 | |
| Collegium Pharmaceutical, INC. | $16.83 | 2020 | |
| Mdd US Operations, LLC | $16.67 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saad Shakir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.